|
EAST RUTHERFORD, N.J., March 23, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the completion of initial engineering studies for its new, large-scale active pharmaceutical ingredient (API) manufacturing plant in Charles City, Iowa. This milestone marks significant progress toward the company's previously announced $120 million investment in expanding its U.S. API manufacturing capabilities. Groundbreaking for the new facility is scheduled to take place in late 2026.
The Charles City expansion will add a new plant with 140,000 liters of capacity, including large-scale and mid-scale reactors, advanced Hastelloy agitated filter dryers, and enhancements to existing manufacturing suites. Upon completion of this phase of expansion, the site will see a 20% increase in large-scale manufacturing capacity. This expansion is designed to support complex chemistry, including controlled substances, highly potent APIs (HPAPI), and commercial-scale liquid phase peptide manufacturing, positioning Cambrex as a trusted partner for pharmaceutical innovators.
In Europe, Cambrex continues to invest with a $30 million expansion underway at its Milan, Italy site. The project will add new analytical development and process R&D capabilities, as well as upgrades to multiple production plants. The Milan R&D expansion is expected to be completed in the second half of 2027, with additional land acquired to support future growth and increased demand for CDMO services.
Claudio Russolo, Chief Operating Officer, commented: "Our Milan, Italy site has a distinguished legacy of supporting pharmaceutical development and manufacturing, and this year marks its 80th anniversary of operation. We are committed to ongoing investments to meet the growing market demand for complex chemistries, including tides, highly potent molecules, and controlled substances."
Cambrex's ongoing investments reflect its dedication to providing modernized solutions for tides and complex small molecule development and manufacturing. The company's science-first approach and commitment to operational excellence ensure that Cambrex remains at the forefront of supporting the next generation of life-changing therapies.
About Cambrex
Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical and IND enabling services.
With 45 years of experience and a growing team of over 2,000 experts servicing global clients from North America and Europe, Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, peptide synthesis, solid-state science, material characterization, and highly potent APIs.
EAST RUTHERFORD, N.J., March 23, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the completion of initial engineering studies for its new, large-scale active pharmaceutical ingredient (API) manufacturing plant in Charles City, Iowa. This milestone marks significant progress toward the company's previously announced $120 million investment in expanding its U.S. API manufacturing capabilities. Groundbreaking for the new facility is scheduled to take place in late 2026.
The Charles City expansion will add a new plant with 140,000 liters of capacity, including large-scale and mid-scale reactors, advanced Hastelloy agitated filter dryers, and enhancements to existing manufacturing suites. Upon completion of this phase of expansion, the site will see a 20% increase in large-scale manufacturing capacity. This expansion is designed to support complex chemistry, including controlled substances, highly potent APIs (HPAPI), and commercial-scale liquid phase peptide manufacturing, positioning Cambrex as a trusted partner for pharmaceutical innovators.
In Europe, Cambrex continues to invest with a $30 million expansion underway at its Milan, Italy site. The project will add new analytical development and process R&D capabilities, as well as upgrades to multiple production plants. The Milan R&D expansion is expected to be completed in the second half of 2027, with additional land acquired to support future growth and increased demand for CDMO services.
Claudio Russolo, Chief Operating Officer, commented: "Our Milan, Italy site has a distinguished legacy of supporting pharmaceutical development and manufacturing, and this year marks its 80th anniversary of operation. We are committed to ongoing investments to meet the growing market demand for complex chemistries, including tides, highly potent molecules, and controlled substances."
Cambrex's ongoing investments reflect its dedication to providing modernized solutions for tides and complex small molecule development and manufacturing. The company's science-first approach and commitment to operational excellence ensure that Cambrex remains at the forefront of supporting the next generation of life-changing therapies.
About Cambrex
Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical and IND enabling services.
With 45 years of experience and a growing team of over 2,000 experts servicing global clients from North America and Europe, Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, peptide synthesis, solid-state science, material characterization, and highly potent APIs.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Cambrex Advances US and European Expansions
MONROE, N.J. and RANCHO CUCAMONGA, Calif., May 9, 2026 /PRNewswire/ -- MimiSilk, the clinical-grade at-home beauty device brand, launched its 2026 Mother's Day campaign, offering a limited-time promotion across its full product collection. The campaign aims to provide consumers with accessible, professional skincare solutions as a gifting choice for the holiday, offering mothers a way to experience medical-grade skin rejuvenation from the comfort of home.
About MimiSilk: Silk Your Skin, Love Your Glow
MimiSilk was founded on a clear mission: to make clinical-grade skincare part of everyday life — offering an effective standalone solution for those seeking skin rejuvenation at home, and a powerful complement to in-clinic treatments for long-term maintenance and lasting results. Its devices are designed to be safe, accessible, and built into daily life – supporting women in building consistent self-care habits that help soften visible signs of aging, restore a natural inner glow, and achieve a texture as smooth as silk. At the core of the brand is a simple belief: beauty is about confidence, control, and taking time to care for yourself.
MimiSilk Iris: Multi-Benefit Anti-Aging in One Device
The flagship product of this season's campaign is the MimiSilk Iris, a non-ablative fractional laser device for at-home use. Operating at a clinically proven 1450 nm wavelength, Iris stimulates natural collagen production to address the appearance of wrinkles, refine pore visibility, and improve overall skin radiance. The device is non-invasive and requires no recovery downtime, making it compatible with a standard nightly skincare routine.
A Limited-Time Mother's Day 2026 Offer
The Mother's Day promotion is available across MimiSilk's collection, catering to both individual consumers and gift shoppers, making it a practical gifting choice for those looking to offer a practical, results-oriented skincare solution.
MimiSilk believes skincare can be more than a beauty step — it can be a meaningful part of how women feel refreshed, confident, and cared for in daily life. A few focused moments each week can become a quiet ritual of restoration and self-care. This Mother's Day and beyond, the brand hopes mothers everywhere feel seen, appreciated, and beautifully radiant.
Further details on the campaign and products are available on the MimiSilk official website.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
MimiSilk Celebrates Mother's Day 2026: The Gift of Skin Confidence
